12 Month Price Forecast For JAGX
Distance to JAGX Price Forecasts
JAGX Price Momentum
🤔 Considering Jaguar Health (JAGX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 2:20 PM UTC
JAGX Analyst Ratings & Price Targets
Based on our analysis of 2 Wall Street analysts, JAGX has a consensus that is bullish. The median price target is $6.00, with forecasts ranging from $6.00 to $6.00. Currently, there are 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With JAGX currently trading at $0.98, the median price forecast suggests a 512.2% upside. The most optimistic forecast comes from at , projecting a 512.2% upside, while at provides the most conservative target, suggesting a 512.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
JAGX Analyst Consensus
JAGX Price Target Range
Latest JAGX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for JAGX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 7, 2021 | Cantor Fitzgerald | Louise Chen | Overweight | Initiates | $5.00 |
| Nov 25, 2020 | H.C. Wainwright | Buy | Reiterates | $0.00 | |
| Nov 25, 2020 | Ladenburg Thalmann | Buy | Initiates | $0.00 | |
| Nov 25, 2020 | Rodman & Renshaw | Buy | Initiates | $0.00 | |
| Nov 25, 2020 | Aegis Capital | Buy | Initiates | $0.00 | |
| Nov 18, 2019 | HC Wainwright & Co. | Buy | Reiterates | $3.00 | |
| Nov 18, 2019 | H.C. Wainwright | Buy | Reiterates | $0.00 | |
| Sep 12, 2019 | Ladenburg Thalmann | Buy | Initiates | $0.00 | |
| Jul 11, 2017 | Rodman & Renshaw | Buy | Initiates | $0.00 | |
| Nov 12, 2015 | Aegis Capital | Buy | Initiates | $0.00 |
Jaguar Health Inc (JAGX) Financial Data
Jaguar Health Inc has a market capitalization of $15.10M with a P/E ratio of 0.0x. The company generates $10.19M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +1.7% quarter-over-quarter, while maintaining an operating margin of -264.5% and return on equity of -290.9%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Jaguar Health Inc (JAGX) Company Overview
About Jaguar Health Inc
Develops plant-based medicines for gastrointestinal issues.
The company operates through two segments: Human Health and Animal Health, creating both prescription and non-prescription products for humans and animals. Its revenue is primarily generated through the sales of its approved drugs, such as Mytesi and Canalevia-CA1, as well as ongoing clinical trials for new treatments aimed at addressing various gastrointestinal conditions.
Jaguar Health is in the process of advancing several products through clinical trials, including Crofelemer and NP-300, which target a range of gastrointestinal disorders. The company is based in San Francisco, California, and focuses on innovative, plant-based therapies that aim to alleviate chronic diarrhea in diverse patient populations.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
49
CEO
Ms. Lisa A. Conte
Country
United States
IPO Year
2015
Website
jaguar.healthJaguar Health Inc (JAGX) Latest News & Analysis
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)
1 day agoJaguar Health's crofelemer showed statistically significant results in a subgroup of adult breast cancer patients from the Phase 3 OnTarget trial, presented at SABCS 2024.
The positive results for crofelemer in breast cancer patients may boost Jaguar Health's stock, indicating potential market approval and increased revenue opportunities in oncology.
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)
4 days agoJaguar Health's Napo Pharmaceuticals will present significant Phase 3 OnTarget trial results for crofelemer in breast cancer patients on December 11, 2024, at the SABCS.
Positive trial results for crofelemer in breast cancer patients could enhance Jaguar Health's market position and attract investor interest, potentially impacting stock performance.
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine
8 days agoJaguar Health's Canalevia®-CA1, a FDA-conditionally approved drug for chemotherapy-induced diarrhea in dogs, is featured in PetVet Magazine. It is a unique canine formulation of crofelemer.
Jaguar Health's FDA approval for Canalevia-CA1 as the first treatment for chemotherapy-induced diarrhea in dogs enhances its market position and potential revenue, signaling growth opportunities for investors.
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins
7 days agoJaguar Health's crofelemer, a plant-based anti-diarrheal, is in five clinical studies for SBS-IF and MVID, with proof-of-concept results expected by Q2 2025. It holds Orphan Drug Designation.
The advancement of crofelemer in clinical trials and its Orphan Drug Designation could lead to market exclusivity, increased sales potential, and positive investor sentiment for Jaguar Health, Inc.
Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
11 days agoJaguar Health, Inc. (NASDAQ:JAGX) will attend the Pet Connect conference on December 3-5, 2024, seeking partners for NP300, a drug candidate for treating diarrhea in dogs.
Jaguar Health seeks partnerships for NP300, a key drug for treating dog diarrhea, signaling potential growth and revenue opportunities, which could influence stock performance and market interest.
Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference
18 days agoJaguar Health, Inc. (NASDAQ:JAGX) CEO Lisa Conte will present at NobleCon20 on December 3, 2024, and virtually on December 5, 2024. Webcast available post-presentation.
Jaguar Health's upcoming presentations at key investor conferences may boost visibility, attract investor interest, and influence stock performance based on CEO insights and company updates.
Frequently Asked Questions About JAGX Stock
What is Jaguar Health Inc's (JAGX) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Jaguar Health Inc (JAGX) has a median price target of $6.00. The highest price target is $6.00 and the lowest is $6.00.
Is JAGX stock a good investment in 2025?
According to current analyst ratings, JAGX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for JAGX stock?
Wall Street analysts predict JAGX stock could reach $6.00 in the next 12 months. This represents a 512.2% increase from the current price of $0.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Jaguar Health Inc's business model?
The company operates through two segments: Human Health and Animal Health, creating both prescription and non-prescription products for humans and animals. Its revenue is primarily generated through the sales of its approved drugs, such as Mytesi and Canalevia-CA1, as well as ongoing clinical trials for new treatments aimed at addressing various gastrointestinal conditions.
What is the highest forecasted price for JAGX Jaguar Health Inc?
The highest price target for JAGX is $6.00 from at , which represents a 512.2% increase from the current price of $0.98.
What is the lowest forecasted price for JAGX Jaguar Health Inc?
The lowest price target for JAGX is $6.00 from at , which represents a 512.2% increase from the current price of $0.98.
What is the overall JAGX consensus from analysts for Jaguar Health Inc?
The overall analyst consensus for JAGX is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are JAGX stock price projections?
Stock price projections, including those for Jaguar Health Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
